Hengeveld, Paul J. http://orcid.org/0000-0002-0070-138X
Ertem, Y. Emre
Dubois, Julie M. N.
Mellink, Clemens H. M.
van der Kevie-Kersemaekers, Anne-Marie
Evers, Ludo M.
Heezen, Kim
Kolijn, P. Martijn
Mook, Olaf R. F.
Motazacker, M. Mahdi
Nasserinejad, Kazem
Kersting, S.
Westerweel, Peter E. http://orcid.org/0000-0002-0746-7039
Niemann, Carsten U. http://orcid.org/0000-0001-9880-5242
Kater, Arnon P.
Langerak, Anton W. http://orcid.org/0000-0002-2078-3220
Levin, Mark-David http://orcid.org/0000-0003-2139-3547
Article History
Received: 18 March 2022
Revised: 5 May 2022
Accepted: 11 May 2022
First Online: 18 May 2022
Competing interests
: SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Roche, Janssen, CSL Behring, Takeda, and Octapharma. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research support via an unrestricted grant from Roche-Genentech and a speaker-fee from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. All other authors declare no competing interests.